Kahira Pharmaceuticals & Chemical Industries Company manufactures and sells pharmaceutical products in Egypt.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م40.00|
|52 Week High||ج.م34.20|
|52 Week Low||ج.م42.99|
|1 Month Change||0%|
|3 Month Change||5.51%|
|1 Year Change||5.63%|
|3 Year Change||18.32%|
|5 Year Change||207.69%|
|Change since IPO||8.87%|
Recent News & Updates
|CPCI||EG Pharmaceuticals||EG Market|
Return vs Industry: CPCI exceeded the EG Pharmaceuticals industry which returned -1.9% over the past year.
Return vs Market: CPCI underperformed the EG Market which returned 12.4% over the past year.
Stable Share Price: CPCI is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: CPCI's weekly volatility (2%) has been stable over the past year.
About the Company
Kahira Pharmaceuticals & Chemical Industries Company manufactures and sells pharmaceutical products in Egypt. Its products include analgesics antipyretics antirheumatic, antibiotics, antidepressants, antidysenterics and enterostatics, antiemetics, antihistamines, antimalarial, cardiacs vascularetics, dermatologicals, endocrine drugs, gastrointestinal drugs, haemostatics, ophthalmics, oro-dentals, pulmonics, single vitamins, sulfhanamides with trimethoprim, topical analgesic antirhumatics, urinary antiseptics, urologics, vaginetics, inhalation surgical products, nutrients, and vitamins and minerals. The company also manufactures veterinary products; and manufactures pharmaceutical products for underlicense companies.
Kahira Pharmaceuticals & Chemical Industries Fundamentals Summary
|CPCI fundamental statistics|
Is CPCI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPCI income statement (TTM)|
|Cost of Revenue||ج.م793.91m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||8.32|
|Net Profit Margin||11.70%|
How did CPCI perform over the long term?See historical performance and comparison
6.7%Current Dividend Yield
Is Kahira Pharmaceuticals & Chemical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CPCI (EGP40) is trading below our estimate of fair value (EGP178.19)
Significantly Below Fair Value: CPCI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CPCI is good value based on its PE Ratio (4.8x) compared to the EG Pharmaceuticals industry average (5.9x).
PE vs Market: CPCI is good value based on its PE Ratio (4.8x) compared to the EG market (11.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CPCI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CPCI is good value based on its PB Ratio (0.8x) compared to the EG Pharmaceuticals industry average (1.3x).
How is Kahira Pharmaceuticals & Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kahira Pharmaceuticals & Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Kahira Pharmaceuticals & Chemical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPCI has high quality earnings.
Growing Profit Margin: CPCI's current net profit margins (11.7%) are higher than last year (10.8%).
Past Earnings Growth Analysis
Earnings Trend: CPCI's earnings have grown by 12.4% per year over the past 5 years.
Accelerating Growth: CPCI's earnings growth over the past year (13.9%) exceeds its 5-year average (12.4% per year).
Earnings vs Industry: CPCI earnings growth over the past year (13.9%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: CPCI's Return on Equity (17.7%) is considered low.
How is Kahira Pharmaceuticals & Chemical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: CPCI's short term assets (EGP915.5M) exceed its short term liabilities (EGP358.2M).
Long Term Liabilities: CPCI's short term assets (EGP915.5M) exceed its long term liabilities (EGP6.6M).
Debt to Equity History and Analysis
Debt Level: CPCI's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CPCI's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CPCI's debt is well covered by operating cash flow (3302.5%).
Interest Coverage: CPCI earns more interest than it pays, so coverage of interest payments is not a concern.
What is Kahira Pharmaceuticals & Chemical Industries's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CPCI's dividend (6.7%) is higher than the bottom 25% of dividend payers in the EG market (2.63%).
High Dividend: CPCI's dividend (6.7%) is low compared to the top 25% of dividend payers in the EG market (7.87%).
Stability and Growth of Payments
Stable Dividend: CPCI has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: CPCI's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (32.2%), CPCI's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Yasser Ahmed Farghali is Executive Managing Director of Kahira Pharmaceuticals & Chemical Industries Company.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Kahira Pharmaceuticals & Chemical Industries Company's employee growth, exchange listings and data sources
- Name: Kahira Pharmaceuticals & Chemical Industries Company
- Ticker: CPCI
- Exchange: CASE
- Founded: 1962
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م597.375m
- Shares outstanding: 14.93m
- Website: https://www.kahira-pharma.com
Number of Employees
- Kahira Pharmaceuticals & Chemical Industries Company
- 4 Abdel-Hamid Eldeeb Street
- Victoria SQ
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 16:18|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.